Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeOne Medicines's gross profit for the
three
months ended in Jun. 2026 was $1,531 Mil. BeOne Medicines's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $5,448 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. BeOne Medicines's gross profit for the
three
months ended in Jun. 2026 was $1,531 Mil. BeOne Medicines's Revenue for the
three
months ended in Jun. 2026 was $1,705 Mil. Therefore, BeOne Medicines's Gross Margin % for the quarter that ended in Jun. 2026 was 89.76%.
BeOne Medicines had a gross margin of 89.76% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of BeOne Medicines was 97.91%. The lowest was 77.12%. And the median was 84.55%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BeOne Medicines had a gross margin of 89.76% for the quarter that ended in Jun. 2026 => Durable competitive advantage
BeOne Medicines Gross Profit Related Terms
BeOne Medicines Gross Profit Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BeOne Medicines's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Gross Profit distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5,448 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BeOne Medicines (ONC) has a Gross Profit of $5,448 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Gross Profit too high?
BeOne Medicines' current Gross Profit is $5,448 Mil. Overall, BeOne Medicines has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Gross Profit compare to RVMD and MRNA?
BeOne Medicines' Gross Profit of $5,448 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Gross Profit is $5,448 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Fairly Valued. The stock's GF Value™ is $378.22, compared to a current price of $359.58 — trading 4.9% below its estimated fair value. The current Gross Profit is $5,448 Mil. BeOne Medicines' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Gross Profit is $5,448 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $359.58 is trading 4.9% below its estimated GF Value™ of $378.22.
GuruFocus considers BeOne Medicines to be Fairly Valued.
Key valuation signals for ONC:
Gross Profit: $5,448 Mil
GF Value™: $378.22 vs. price of $359.58 (4.9% below fair value)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
80GF Score
Get the complete analysis for ONC
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
